Author

H. Hammerlindl

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:metagenomics· 1 Assay:organoid / primary culture· 1 Assay:proteomics· 1

Frequent Co-Authors

H. Schaider· 2 shared A. B. Chase· 1 shared A. Bogdanov· 1 shared A. H. Benfield· 1 shared A. J. O'Donoghue· 1 shared A. M. Kane· 1 shared B. A. Leggett· 1 shared B. Salik· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H. Schaider

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression

H. P. Nguyen, R. Sheng, E. Murray, Y. Ito, M. Bruck, C. Biellak, K. An, F. Lynce, D. A. Dillon, M. J. M. Magbanua, L. A. Huppert, H. Hammerlindl, L. Esserman, J. M. Rosenbluth, N. Ahituv

The paper shows engineered adipocytes can suppress cancer progression by competing for nutrients in multiple cancer types.

bioRxiv · Mar 28, 2023 · PreprintCancer Biology

Small Molecule in situ Resin Capture - A Compound First Approach to Natural Product Discovery.

A. Bogdanov, M. N. Salib, A. B. Chase, H. Hammerlindl, M. N. Muskat, S. Luedtke, E. Barbosa Da Silva, A. J. O'Donoghue, L. F. Wu, S. J. Altschuler, T. F. Molinski, P. R. Jensen

This paper introduces a compound-first approach to natural product discovery called SMIRC, which captures structurally complex small molecules directly from environments, leading to the discovery of new compounds and classes.

bioRxiv · Mar 2, 2023 · PreprintBiochemistry

Membrane-active peptides escape drug-resistance in cancer

A. H. Benfield, F. Vernen, R. S. E. Young, F. N. Bufi, H. Hammerlindl, D. J. Craik, H. Schaider, N. Lawrence, S. J. Blanksby, S. T. Henriques

This study shows membrane-active peptides can kill drug-resistant melanoma cells without inducing resistance, suggesting their potential as therapeutic agents.

bioRxiv · Oct 27, 2022 · PreprintCancer Biology

Aspirin synergizes with regorafenib to reduce growth of colorectal cancer

C. Su, L. J. Fennell, C. E. Bond, A. M. Kane, G. Kerr, T. Jarde, D. Micati, R. M. Engel, W. H. Chan, S. Hlavca, S. Archer, P. J. McMurrick, H. Hammerlindl, F. Lim, B. Salik, , V. L. Whitehall

This study shows that aspirin and regorafenib together reduce colorectal cancer growth in preclinical models by inhibiting the PI3K-Akt-mTOR pathway and activating AMPK.

bioRxiv · Feb 11, 2022 · PreprintCancer Biology